Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Accounting

Advertising

Consulting

Legal

Office

Officer and director remuneration

Patent fees

Depreciation

Directors Fees

Taxes

Goodwill impairment

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Sunshine Biopharma

Sunshine Biopharma, Inc. engages in the research, development, and commercialization of oncology and antiviral drugs. It is also involved in the development and commercialization of science-based nutritional supplements. Its products include treatment for Coronavirus infections and anticancer drugs. The company was founded on August 31, 2006 and is headquartered in Pointe-Claire, Canada.

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Sunshine Biopharma, Inc. is a pharmaceutical company, which engages in the research, development, and commercialization of oncology and antiviral drugs. It is also involved in the development and commercialization of science-based nutritional supplements. The firm's product includes treatment for Coronavirus infections and anticancer drugs. The company was founded on August 31, 2006 and is headquartered in Fort Lauderdale, FL.

Aterian

Recon Technology

Here's what you need to know about trading penny stocks on April 5th The post Trading Penny Stocks, April 5th, SBFM and TWTR Explode appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Trading Penny Stocks, April 5th, SBFM and TWTR Explode

Shares of SBFM stock are on the move and here's why. The post Best Penny Stocks Today: Why SBFM Stock Is Moving 175%+ appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Best Penny Stocks Today: Why SBFM Stock Is Moving 175%+

A Potential Multi-Billion Dollar Global Market Opportunity for Cancer Treatments A Potential Multi-Billion Dollar Global Market Opportunity for Cancer Treatments

Sunshine Biopharma's Newly Designed mRNA Molecules Prove Effective Against Multidrug Resistant Cancer Cells

NEW YORK, NY / ACCESSWIRE / March 15, 2022 / Aegis Capital Corp. acted as Exclusive Placement Agent on an $8 Million Private Placement for Sunshine Biopharma Inc. (NASDAQ:SBFM) About Sunshine Biopharma, Inc. Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of the ongoing COVID-19 pandemic that has claimed the lives of over 5.3 million people worldwide since it first appeared in December 2019. There are currently no drugs that can effectively arrest replication of the virus in people who have contracted the illness.

Aegis Capital Corp. acted as Exclusive Placement Agent on an $8 Million Private Placement for Sunshine Biopharma Inc. (NASDAQ: SBFM)

MONTREAL, March 14, 2022 (GLOBE NEWSWIRE) -- Sunshine Biopharma, Inc. (NASDAQ: “SBFM” and “SBFMW”) (the “Company” or “Sunshine Biopharma”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today closed its previously announced private placement pursuant to a securities purchase agreement entered into on March 10, 2022 with certain institutional and accredited investors.

Sunshine Biopharma, Inc. Announces Closing of $8.0 Million Private Placement Priced At-the-Market

MONTREAL, March 10, 2022 (GLOBE NEWSWIRE) -- Sunshine Biopharma, Inc. (NASDAQ: “SBFM” and “SBFMW”) (the “Company” or “Sunshine Biopharma”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it entered into a securities purchase agreement with certain institutional and accredited investors for aggregate gross proceeds of approximately $8.0 million, before deducting fees to the placement agent and other offering expenses payable by the Company.

Sunshine Biopharma, Inc. Announces Pricing of $8.0 Million Private Placement Priced At-the-Market

Today, investors in Sunshine Biopharma and SBFM stock are seeing impressive gains. The stock is surging more than 160% on intense interest.

SBFM Stock Alert: 7 Things to Know as Sunshine Biopharma Skyrockets

MONTREAL, Feb. 25, 2022 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (NASDAQ: “SBFM” and SBFMW) (the “Company” or “Sunshine Biopharma”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs today announced that it has entered into an agreement with the University of Arizona for the purposes of advancing the development of novel PLpro inhibitors discovered by University of Arizona and University of Illinois Chicago researchers. The development of the Company's lead PLpro inhibitor, SBFM-PL4, is currently continuing at the University of Georgia. At the University of Arizona, the research effort will focus on determining the in vivo safety, pharmacokinetics, and dose selection properties of 3 university owned PLpro inhibitors followed by efficacy testing in MA10 mice infected with SARS-CoV-2. Molecules showing efficacy in infected mice will be advanced to human trials.

Sunshine Biopharma Expands Anti-Coronavirus Drug Development Program By Signing A Collaboration Agreement With The University Of Arizona

NEW YORK, NY / ACCESSWIRE / February 17, 2022 / Aegis Capital Corp. acted as Sole Bookrunner on an Uplist of an $8 Million Underwritten Public Offering for Sunshine Biopharma Inc. (NASDAQ:SBFM; SBFMW) About Sunshine Biopharma, Inc. Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of the ongoing COVID-19 pandemic that has claimed the lives of over 5.3 million people worldwide since it first appeared in December 2019. There are currently no drugs that can effectively arrest replication of the virus in people who have contracted the illness.

Aegis Capital Corp. acted as Sole Bookrunner on an Uplist of an $8 Million Underwritten Public Offering for Sunshine Biopharma Inc. (NASDAQ: SBFM; SBFMW)

MONTREAL, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Sunshine Biopharma, Inc. (NASDAQ: “SBFM” and “SBFMW”) (the “Company” or “Sunshine Biopharma”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, announced today the closing of its underwritten public offering of 1,882,353 units at a price to the public of $4.25 per unit, for aggregate gross proceeds of $8 million, prior to deducting underwriting discounts, commissions and other estimated offering expenses. Each unit consists of one share of common stock, par value $0.001 per share, and two warrants, each warrant exercisable for one share of common stock with an exercise price of $4.25.

Sunshine Biopharma, Inc. Announces Closing of $8 Million Public Offering and Uplisting to the Nasdaq Capital Market

MONTREAL, Feb. 15, 2022 (GLOBE NEWSWIRE) -- Sunshine Biopharma, Inc. (NASDAQ: “SBFM” and “SBFMW”) (the "Company" or "Sunshine Biopharma"), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, announced today the pricing of its underwritten public offering of 1,882,353 units at a price to the public of $4.25 per unit, for aggregate gross proceeds of $8 million, prior to deducting underwriting discounts, commissions and other estimated offering expenses. Each unit consists of one share of common stock, par value $0.001 per share, and two warrants, each warrant exercisable for one share of common stock. The common stock and warrants are immediately separable from the Units and will be issued separately. The warrants are exercisable immediately, expire five years from the date of issuance and have an exercise price of $4.25.

Sunshine Biopharma, Inc. Announces Pricing of $8 Million Public Offering and Uplisting to the Nasdaq Capital Market

MONTREAL, Dec. 22, 2021 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that on December 20, 2021, the Company issued 2,904,833 shares of Common Stock in favor of RB Capital Partners, Inc. (“RB Capital”) in connection with the conversion of $1,361,000 in convertible debt at an average conversion price of $0.47 per share. The total debt remaining on the books of the Company is $1,900,000 convertible at an average price of $0.30 per share with maturity dates in April, July and August 2023.

Sunshine Biopharma Announces $1,361,000 in Debt Reduction

Independent Directors Added as Part of Company's Application Process to Uplist to Nasdaq Independent Directors Added as Part of Company's Application Process to Uplist to Nasdaq

Sunshine Biopharma Expands Board of Directors

MONTREAL, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has filed a patent application for a potential new treatment for neurodegenerative disorders. Sunshine Biopharma's patent application contains experimental results showing that certain mRNA molecules provide protective effects against oxidative stress in differentiated neuronal cells, a process that mimics neuronal degeneration. This new patent application has a priority date of October 1, 2021.

Sunshine Biopharma Files a Patent Application Covering mRNA Molecules for Treatment of Neurodegenerative Diseases

MONTREAL, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (OTC Pink: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs today announced that it mapped the mutations found in Delta and the other variants of concern (“VOC”) identified to date and determined that the majority of the mutations are in the Spike protein and only a few fall within the genomic sequences that encode nsp3, a multi-domain protein that includes the PLpro enzyme. Serendipitously, no mutations mapped within the domain comprising the PLpro catalytic core. These finding indicate that our PLpro inhibitors currently under development at the University of Georgia would likely be effective against all of the VOC.

Sunshine Biopharma's Coronavirus Treatment Anticipated to be Effective Against Delta and the Other Variants of Concern

MONTREAL, July 27, 2021 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, is pleased to announce that we have opened an official company Twitter account under the handle @SunshineBio1.

Sunshine Biopharma Opens Twitter Account For Increased Shareholder Engagement

MONTREAL, July 20, 2021 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has received additional funding from RB Capital Partners, Inc. (“RB Capital”) in the amount of $900,000. The investment is in the form of convertible debt with a conversion price set a premium to market of $0.30 per share. This brings the total to just over $3,500,000 that RB Capital has invested in Sunshine Biopharma to date. Sunshine Biopharma will use the proceeds of this new financing to advance the development of the COVID-19 protease inhibitor treatment and Adva-27a, the Company's flagship anticancer compound.

Sunshine Biopharma Receives $0.9 Million in Additional Funding From RB Capital

MONTREAL, July 08, 2021 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has succeeded in inhibiting the activity of Nrf2 using mRNA vaccine technology. Nrf2 is a transcription factor responsible for activation of oxidative stress genes as well as the cancer multidrug resistance genes, MDR1 (p-Glycoprotein), MRP1 and BCRP. By temporarily inhibiting Nrf2 activity with an mRNA injection immediately before or during chemotherapy, the Company hopes to achieve enhanced performance of anticancer drugs and consequently better overall therapeutic outcomes for cancer patients. In separate studies using a small molecule inhibitor of Nrf2, the Company results showed that the activity of a test anticancer drug (Etoposide) was enhanced approximately 4-fold. These studies were performed in MCF-7/MDR, a multidrug resistant breast cancer cell line.

Sunshine Biopharma Employs mRNA Vaccine Technology to Expand Its Fight Against Multidrug Resistant Cancer

Acasti Pharma

1847 GOEDEKER INC.

Globalstar

Histogen

Regulus Therapeutics

Senseonics Holdings

Looking for the best penny stocks to watch in July? Check these 7 out for your list The post Reddit Penny Stocks to Buy?

Reddit Penny Stocks to Buy? 7 You Need to Know About In July

MONTREAL, May 20, 2021 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has paid off $250,000 in variable rate convertible debt and is planning to soon eliminate the two similar items remaining on the books of the Company. The Company's application for uplisting to the OTCQB had been declined due to outstanding variable rate loans which were on the Company's financial statements at the time of the application. The Company can re-apply in October 2021.

Sunshine Biopharma Eliminates $250,000 in Variable Rate Convertible Debt and Provides an Update on Status of OTCQB Uplisting

MONTREAL, March 23, 2021 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has received a total of $2,054,000 to date from the recently announced committed minimum financing of $2,000,000 with RB Capital Partners Inc. The financing is in the form of fixed-price convertible debt which now stands at a weighted average conversion price of $0.43 per share. This debt is obligatorily convertible on or before the maturity date.

Sunshine Biopharma Reaches $2,000,000+ Financing for Coronavirus Treatment

MONTREAL, March 01, 2021 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a leader in nutrition research and development today unveiled its new eCommerce website, Nutrition.SunshineBiopharma.com. The site boasts over 20 products ranging from essential amino acids and rich protein powders to balanced vitamins and crucial micronutrients. All of Sunshine Biopharma's nutritional supplements are manufactured and tested in Canada under strict GMP conditions and Health Canada oversight. Some of the products listed on Nutrition.Sunshinebiopharma.com will continue to be available on Amazon.com and Amazon.ca.

UPDATE -- Sunshine Biopharma Launches eCommerce Store for Its Science-Based Nutritional Supplements

Phoenix, Arizona--(Newsfile Corp. - February 17, 2021) - The Stock Day Podcast welcomed Sunshine Biopharma (OTC Pink: SBFM) ("the Company"), a company engaged in the development of Adva-27a, a unique anticancer compound, as well as the development of a treatment for COVID-19. CEO of the Company, Dr. Steve Slilaty, joined Stock Day host, Everett Jolly. Jolly began the interview by commenting on the Company's significant increase in stock price over the past several months....

Sunshine Biopharma Discusses the Progress of Its COVID-19 and Anticancer Compounds with The Stock Day Podcast

MONTREAL, QC / ACCESSWIRE / January 14, 2021 / Sunshine Biopharma Inc. (OTC PINK:SBFM), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has received the fourth tranche of funding under the recently announced committed minimum financing of $2,000,000 with RB Capital Partners Inc. This brings the total to $1,050,000 that the Company has received to date under this financing. The proceeds will be used for the ongoing development of the Company's Coronavirus Treatment on a priority basis and the clinical development of Adva-27a, the Company's flagship anticancer compound targeted for pancreatic cancer.

News for Sunshine Biopharma Stock (SBFM)